Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Apple Turns 50: From Garage Startup to AI Crossroads 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Britain Courts Anthropic Amid US Defense Department Dispute 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
WALTHAM, Mass., Nov. 23, 2016 -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the closing of its follow-on public offering of 6,250,000 American Depositary Shares (“ADSs”), each representing 13 of its ordinary shares, par value $0.0001 per share, at a price to the public of $32.00 per ADS. BeiGene offered 5,781,250 ADSs, and certain selling shareholders offered 468,750 ADSs. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 937,500 ADSs from BeiGene.
BeiGene intends to use proceeds from the offering for working capital and general corporate purposes, including research and development activities. BeiGene will not receive proceeds from any sale of ADSs by the selling shareholders.
Morgan Stanley, Goldman, Sachs & Co. and Cowen and Company acted as joint book-running managers. Baird and William Blair & Company, L.L.C. acted as co-managers.
A registration statement relating to these securities was filed with, and declared effective by, the Securities and Exchange Commission. The offering was made only by means of a prospectus, copies of which may be obtained for free from the offices of Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, or email: [email protected]; or Cowen and Company, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, United States, Attn.: Prospectus Department or by calling +1 (631) 274 2806.
About BeiGene
BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 300 scientists, clinicians and staff in mainland China, the United States, Australia and Taiwan, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients.
Investor/Media Contact Lucy Li, Ph.D. +1 781-801-1800 [email protected] [email protected]
